Disease management programmes in Germany – IQWiG says it’s time for an update
Hi again, welcome to the series in quality assurance initiatives, starting with disease management programmes in Germany. This post will cover: Next
Tag: G-BA
How will German early benefit assessments change in the future?
Welcome to the last post in the HTA series, focusing on the changes to HTA and early benefit assessments in Germany in
How does the G-BA pick the appropriate comparator?
Welcome! In this post, I am going through the steps on how the G-BA chooses the appropriate comparative therapy (ACT). I conclude
Which endpoints are important to the G-BA and IQWiG?
Welcome, this week’s post on the G-BA’s views on endpoints is the second article in the benefit assessments series. You’ll learn about:
Regular and abbreviated early benefit assessments – Is this the end of orphan drug privileges?
This is the first article in a series about maybe the most important topic influencing market access in Germany: HTAs or early